前列腺癌放疗中水凝胶间隔物的前瞻性分析
该前瞻性研究纳入76例T1-T3a前列腺癌患者,在IMRT或VMAT前于直肠周围注射水凝胶间隔物(HS)。结果显示无术后并发症,直肠受照剂量体积降低,急性1级胃肠道毒性发生率为21%(16/76)且3个月内完全缓解,晚期1级毒性为3%(2/76),无≥2级毒性。
要点
- HS注射无术后并发症,可降低直肠受照剂量体积。
- 急性1级胃肠道毒性21%(16/76),3个月内完全缓解。
- 晚期1级毒性3%(2/76),无≥2级急慢性胃肠道毒性。
核心结论
- 水凝胶间隔物注射可减少直肠受照剂量体积,且胃肠道毒性轻微,无论前列腺大小。
研究设计与样本
- 前瞻性研究,76例临床分期T1-T3a前列腺癌患者在全麻下植入基准标记并注射水凝胶间隔物,随后接受IMRT或VMAT。
主要发现
- 无术后并发症报告。
- 直肠接受70Gy、75Gy、78Gy的剂量体积(rV70、rV75、rV78)分别为7.8%、3.6%、0.4%。
- 急性1级胃肠道毒性发生率为21%(16/76),均在治疗结束后3个月内完全缓解。
- 晚期1级胃肠道毒性发生率为3%(2/76)。
- 无患者发生急性或晚期≥2级胃肠道毒性。
关键数值与推荐
- 前列腺平均大小为66.0 mm(范围25.0-187.0 mm)。
- 直肠剂量体积参数:rV70=7.8%,rV75=3.6%,rV78=0.4%。
- 急性1级胃肠道毒性21%(16/76),晚期1级胃肠道毒性3%(2/76)。
临床怎么用
- 在前列腺癌放疗前注射水凝胶间隔物可减少直肠高剂量照射,降低胃肠道毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report on the dosimetric benefits and late toxicity outcomes after injection of hydrogel spacer (HS) between the prostate and rectum for patients treated with prostate radiotherapy (RT). PATIENTS AND METHODS: In all, 76 patients with a clinical stage of T1-T3a prostate cancer underwent general anaesthesia for fiducial marker insertion plus injection of the HS into the perirectal space before intensity-modulated RT (IMRT) or volumetric-modulated arc RT (VMAT). HS safety, dosimetric benefits, and the immediate- to long-term effects of gastrointestinal (GI) toxicity were assessed. RESULTS: There were no postoperative complications reported. The mean (range) prostate size was 66.0 (25.0-187.0) mm. Rectal dose volume parameters were observed and the volume of rectum receiving 70 Gy (rV70 ), 75 Gy (rV75 ) and 78 Gy (rV78 ) was 7.8%, 3.6% and 0.4%, respectively. In all, 21% of patients (16/76) developed acute Grade 1 GI toxicities, but all were resolved completely by 3 months after treatment; whilst, 3% of patients (2/76) developed late Grade 1 GI toxicities. No patients had acute or late Grade ≥2 GI toxicities. CONCLUSION: Injection of HS resulted in a reduction of irradiated rectal dose volumes along with minimal GI toxicities, irrespective of prostate size.
引用
- Chao M, Ho H, Chan Y, et al. Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy. BJU Int. 2018. PMID: 29520983. doi:10.1111/bju.14192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。